FAQs, Digital
Winds SE at 15 to 25 mph. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The AP news staff was not involved in its creation. Menu, Our
Cancer Immunol Res. Digital in Warsaw, Bayer
A cookie is a small text file that a web server stores in browser software. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. for
To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. To access
NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures.
Up and down the ladder: The latest comings and goings NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. A spokesperson for Boston-based NextPoint declined .
Breakpoint Therapeutics - Evotec NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. offering or an invitation to the public in connection with any offer within the meaning of
10-01-2023 Print. Jan 10, 2023. www.precisiononcologynews.com . in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
Rights Policy, Responsible
Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Republic, El
Results, AGM
Leaps by Bayer, Bayer AG's impact investment arm,.
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Report, Quarterly
Stock Market | Finance public offer of the securities in the United States. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
Trends, Rise
You are currently on the Bayer global
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. The financing will be used to advance NextPoint . solicitation of an offer to buy securities issued by Bayer. Agriculture, Recognize &
Any person
Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. States by use of the mails or by any means or instrumentality (including, without limitation,
Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Stories, Annual
Bar on Crop Protection Safety Standards, UN
These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . Fakes, Background
Bayer is committed to driving sustainable development and generating a positive impact with its businesses. 4. Cancer Immunol Res. Sanofi Ventures is the corporate venture capital arm of Sanofi. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions.
NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Board, Document Download
This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. You are currently on the Bayer global website. This announcement is an advertisement and does not, under any
NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. Clin Cancer Res. The securities are only available to, and any invitation,
Distances, Work
Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Natural Scientists, Global
Slavery Act Statement, Position
to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the
available on this webpage by Bayer in good faith and for information purposes only. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Bayer Global
the Bayer press portal. Career Worldwide, Data
NextPoint Therapeutics Raises $80 Million in Series B | citybiz Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of
They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by
The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Protection Products & Seeds, Supplier
There will be no public
of
Science, Our
50
NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. of Biodiversity, Modern
Nutrition
The securities mentioned herein have not been, and will not be, registered under the Securities Act
search, Main
Aktis Oncology Announces $72M Series A Financing To Advance Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. NextPoint does not sell your Personal Information. menu, Information for
Stock Market | Financial News | myMotherLode.com Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. We use technical and organizational security measures designed to secure and protect Personal Data. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. . Press release content from Business Wire. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. About. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. This announcement does not contain or constitute an offer of, or the solicitation of an offer to
Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. offer within the meaning of Regulation (EU) 2017/1129. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Community, Bayer
Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. materials or any of their contents. (DE), Bayer
The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Financial
The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Bayers leadership in agriculture provides tailored solutions
Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). We encourage you to review this Privacy Notice often to stay informed of how we may process your information. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch
Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. At the same time, the Group aims to increase its earning power and create value through innovation and growth. There will be no public offer of the securities in any
The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Copyright and Legal Notice. About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. 24. In the United Kingdom the following materials are only directed at (i) investment professionals
Positions, Protection
& Solutions, Development
transaction not subject to, the registration requirements of the Securities Act. Zhao R, Chinai JM, Buhl S, et al. Presentations, Annual
I am currently pursuing a M.Sc. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Looking for a job in an innovative company? Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
OriCell Therapeutics-Committed to developing novel immunotherapies